Valmet’s Interim Review January 1 – September 30, 2026: Strong orders received and increased comparable EBITA

For July–September 2026, Valmet’s orders received rose 30% to EUR 1,408 million, including 25% organic growth, supported by biomaterial services, Process Performance Solutions and biomaterial capital projects. Net sales increased 5% to EUR 1,360 million, and the release headline reports increased comparable EBITA; the provided article excerpt contains no EBITA figure.

Analysis

The key signal is that demand is leading reported sales: if the order growth is durable and converts into backlog, revenue support extends beyond this quarter. The mix matters more than the headline rate. Service and performance-solution orders may offer steadier conversion than large biomaterial capital projects; the excerpt does not disclose enough to establish how much of the increase is recurring, profitable, or cancellable. Increased comparable EBITA is directionally supportive, but without the margin bridge, backlog, cash conversion, or full-year outlook, it does not yet prove operating leverage.

Near term, the stock’s reaction will depend on whether investors view the order acceleration as broad-based or project-lumpy; the excerpt suggests both service strength and a strong capital-project quarter. Over 1–3 months, watch order conversion, cancellations, and margin on new projects. Over 6–18 months, sustained backlog conversion could support estimates, while execution delays or weaker customer capex could turn today’s orders into deferred rather than incremental earnings. Andritz is a relevant peer to monitor for evidence that biomaterial investment is sector-wide; the data here do not establish a direct competitive win or loss.

Key Decisions for Investors

• Do not chase VALMT solely on the order headline before reviewing the complete interim report and the market’s initial reaction. The supplied excerpt omits backlog, comparable EBITA details, cash flow, and guidance.
• Conditional idea: consider a measured long in VALMT if the full release confirms healthy order conversion and stable or improving comparable EBITA margin, and the share price does not already discount a sustained acceleration. Reassess if the next reporting period shows orders falling below sales without backlog support.
• Treat the capital-project component as a quality check, not an automatic positive: verify project terms, cancellation exposure, and delivery timing. If the order increase is concentrated in a few large projects while services weaken, avoid extrapolating the quarterly growth rate.
• Monitor Andritz and broader pulp, paper, and biomaterial-capex indicators as a read-through, not as proof of shared order momentum. A deterioration in customer investment plans or a material downward revision to Valmet’s conversion or margin outlook would falsify the constructive thesis.